In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1
- PMID: 20078084
- PMCID: PMC2839030
- DOI: 10.1021/tx900348v
In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1
Abstract
A computational study was undertaken to understand the nature of binding and the structural features that play a significant role in the binding of arylacetylene molecules to cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1. Nine polycyclic arylacetylenes determined to be mechanism-based P450 enzyme inhibitors were studied. The lack of polar substituents in these compounds causes them to be incapable of hydrogen bonding to the polar protein residues. The four P450 enzymes of interest all have phenylalanine residues in the binding pocket for potential pi-pi interactions with the aromatic rings of the inhibitors. The inhibition potency of these arylacetylenes toward P450s 1A1 and 2B1 showed a dependence on the proximity of the inhibitor's triple bond to the prosthetic heme Fe of the enzyme. In P450 enzyme 1A2, the inhibitor's potency showed more dependence on the pi-pi interactions of the inhibitor's ring systems with the phenylalanine residues of the protein, with the proximity of the inhibitor triple bond to the heme Fe weighing in as the second most important factor. The results suggest that maximizing the pi-pi interactions with phenylalanine residues in the binding pocket and optimum proximity of the acetylene moiety to the heme Fe will provide for a substantial increase in the potency of the polyaromatic hydrocarbon mechanism-based inhibitors. A fine balance of these two aspects of binding coupled with attention to supplementing hydrophobic interactions could address potency and selectivity issues for these inhibitors.
Figures






Similar articles
-
Inhibition of cytochrome p450 enzymes by quinones and anthraquinones.Chem Res Toxicol. 2012 Feb 20;25(2):357-65. doi: 10.1021/tx2004163. Epub 2012 Jan 10. Chem Res Toxicol. 2012. PMID: 22185593 Free PMC article.
-
Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies.Molecules. 2012 Aug 3;17(8):9283-305. doi: 10.3390/molecules17089283. Molecules. 2012. PMID: 22864238 Free PMC article. Review.
-
Ortho-Methylarylamines as Time-Dependent Inhibitors of Cytochrome P450 1A1 Enzyme.Drug Metab Lett. 2017;10(4):270-277. doi: 10.2174/1872312810666161220155226. Drug Metab Lett. 2017. PMID: 28000546 Free PMC article.
-
Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1.Chem Res Toxicol. 1998 Sep;11(9):1048-56. doi: 10.1021/tx980090+. Chem Res Toxicol. 1998. PMID: 9760279
-
Cytochrome P450 family 1 inhibitors and structure-activity relationships.Molecules. 2013 Nov 25;18(12):14470-95. doi: 10.3390/molecules181214470. Molecules. 2013. PMID: 24287985 Free PMC article. Review.
Cited by
-
Review of Ligand Specificity Factors for CYP1A Subfamily Enzymes from Molecular Modeling Studies Reported to-Date.Molecules. 2017 Jul 8;22(7):1143. doi: 10.3390/molecules22071143. Molecules. 2017. PMID: 28698457 Free PMC article. Review.
-
QSAR models of cytochrome P450 enzyme 1A2 inhibitors using CoMFA, CoMSIA and HQSAR.SAR QSAR Environ Res. 2011 Oct;22(7-8):681-97. doi: 10.1080/1062936X.2011.623320. Epub 2011 Oct 17. SAR QSAR Environ Res. 2011. PMID: 22004550 Free PMC article.
-
Inhibition of cytochrome p450 enzymes by quinones and anthraquinones.Chem Res Toxicol. 2012 Feb 20;25(2):357-65. doi: 10.1021/tx2004163. Epub 2012 Jan 10. Chem Res Toxicol. 2012. PMID: 22185593 Free PMC article.
-
Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies.Molecules. 2012 Aug 3;17(8):9283-305. doi: 10.3390/molecules17089283. Molecules. 2012. PMID: 22864238 Free PMC article. Review.
-
Ortho-Methylarylamines as Time-Dependent Inhibitors of Cytochrome P450 1A1 Enzyme.Drug Metab Lett. 2017;10(4):270-277. doi: 10.2174/1872312810666161220155226. Drug Metab Lett. 2017. PMID: 28000546 Free PMC article.
References
-
- Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996;6:1–42. - PubMed
-
- Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993;12:1–51. - PubMed
-
- Guengerich FP. Cytochrome P450: What Have We Learned and What Are the Future Issues? Drug Metabol Rev. 2004;36:159–197. - PubMed
-
- Agundez JA. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab. 2004;5:211–224. - PubMed
-
- Shimada T, Oda Y, Gillam EM, Guengerich FP, Inoue K. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. Drug Metab Dispos. 2001;29:1176–1182. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous